Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children - United States, 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 14;73(10):225-228. doi: 10.15585/mmwr.mm7310a2.NO ABSTRACTPMID:38488279 | DOI:10.15585/mmwr.mm7310a2 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - March 15, 2024 Category: Epidemiology Authors: Anna R Yousaf Katherine N Lindsey Michael J Wu Ami B Shah Rebecca J Free Regina M Simeone Laura D Zambrano Angela P Campbell MIS-C Surveillance Authorship Group Source Type: research

Notes from the Field: Surveillance for Multisystem Inflammatory Syndrome in Children - United States, 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 14;73(10):225-228. doi: 10.15585/mmwr.mm7310a2.NO ABSTRACTPMID:38488279 | DOI:10.15585/mmwr.mm7310a2 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - March 15, 2024 Category: Epidemiology Authors: Anna R Yousaf Katherine N Lindsey Michael J Wu Ami B Shah Rebecca J Free Regina M Simeone Laura D Zambrano Angela P Campbell MIS-C Surveillance Authorship Group Source Type: research

Outbreak Linked to Morel Mushroom Exposure - Montana, 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 14;73(10):219-224. doi: 10.15585/mmwr.mm7310a1.ABSTRACTDuring March-April 2023, a total of 51 persons reported mild to severe gastrointestinal illness after eating at restaurant A in Bozeman, Montana. The outbreak resulted in multiple severe outcomes, including three hospitalizations and two deaths. After an inspection and temporary restaurant closure, the Montana Department of Public Health and Human Services and Montana's Gallatin City-County Health Department collaborated with CDC to conduct a matched case-control study among restaurant patrons to help identify the source of the outbr...
Source: MMWR Morb Mortal Wkl... - March 14, 2024 Category: Epidemiology Authors: Heather Demorest Rachel Hinnenkamp Maggie Cook-Shimanek Alyssa N Troeschel Michael Yeh Thao-Phuong Christy Hallett David Kuai Johnni Daniel Andrea Winquist Source Type: research

Erratum: Vol. 72, No. 36
MMWR Morb Mortal Wkly Rep. 2024 Mar 14;73(10):231. doi: 10.15585/mmwr.mm7310a4.NO ABSTRACTPMID:38483846 | DOI:10.15585/mmwr.mm7310a4 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - March 14, 2024 Category: Epidemiology Source Type: research

Notes from the Field: Measles Outbreak - Cook County, Illinois, October-November 2023
MMWR Morb Mortal Wkly Rep. 2024 Mar 14;73(10):229-230. doi: 10.15585/mmwr.mm7310a3.NO ABSTRACTPMID:38483848 | DOI:10.15585/mmwr.mm7310a3 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - March 14, 2024 Category: Epidemiology Authors: Kelley Bemis Mabel Frias Sheila Giovanni Tarek Shackour Heather D Reid Jodi Morgan Michael TeKippe Demian Christiansen Source Type: research

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infect...
Source: MMWR Morb Mortal Wkl... - March 8, 2024 Category: Epidemiology Authors: Heidi L Moline Ayzsa Tannis Ariana P Toepfer John V Williams Julie A Boom Janet A Englund Natasha B Halasa Mary Allen Staat Geoffrey A Weinberg Rangaraj Selvarangan Marian G Michaels Leila C Sahni Eileen J Klein Laura S Stewart Elizabeth P Schlaudecker Pe Source Type: research

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infect...
Source: MMWR Morb Mortal Wkl... - March 8, 2024 Category: Epidemiology Authors: Heidi L Moline Ayzsa Tannis Ariana P Toepfer John V Williams Julie A Boom Janet A Englund Natasha B Halasa Mary Allen Staat Geoffrey A Weinberg Rangaraj Selvarangan Marian G Michaels Leila C Sahni Eileen J Klein Laura S Stewart Elizabeth P Schlaudecker Pe Source Type: research

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infect...
Source: MMWR Morb Mortal Wkl... - March 8, 2024 Category: Epidemiology Authors: Heidi L Moline Ayzsa Tannis Ariana P Toepfer John V Williams Julie A Boom Janet A Englund Natasha B Halasa Mary Allen Staat Geoffrey A Weinberg Rangaraj Selvarangan Marian G Michaels Leila C Sahni Eileen J Klein Laura S Stewart Elizabeth P Schlaudecker Pe Source Type: research

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infect...
Source: MMWR Morb Mortal Wkl... - March 8, 2024 Category: Epidemiology Authors: Heidi L Moline Ayzsa Tannis Ariana P Toepfer John V Williams Julie A Boom Janet A Englund Natasha B Halasa Mary Allen Staat Geoffrey A Weinberg Rangaraj Selvarangan Marian G Michaels Leila C Sahni Eileen J Klein Laura S Stewart Elizabeth P Schlaudecker Pe Source Type: research

Early Estimate of Nirsevimab Effectiveness for Prevention of Respiratory Syncytial Virus-Associated Hospitalization Among Infants Entering Their First Respiratory Syncytial Virus Season - New Vaccine Surveillance Network, October 2023-February 2024
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):209-214. doi: 10.15585/mmwr.mm7309a4.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization among infants in the United States. In August 2023, CDC's Advisory Committee on Immunization Practices recommended nirsevimab, a long-acting monoclonal antibody, for infants aged <8 months to protect against RSV-associated lower respiratory tract infection during their first RSV season and for children aged 8-19 months at increased risk for severe RSV disease. In phase 3 clinical trials, nirsevimab efficacy against RSV-associated lower respiratory tract infect...
Source: MMWR Morb Mortal Wkl... - March 8, 2024 Category: Epidemiology Authors: Heidi L Moline Ayzsa Tannis Ariana P Toepfer John V Williams Julie A Boom Janet A Englund Natasha B Halasa Mary Allen Staat Geoffrey A Weinberg Rangaraj Selvarangan Marian G Michaels Leila C Sahni Eileen J Klein Laura S Stewart Elizabeth P Schlaudecker Pe Source Type: research

Years of Potential Life Lost and Mean Age of Adults Experiencing Nontraumatic, Out-of-Hospital Cardiac Arrests - Chicago, 2014-2021
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):199-203. doi: 10.15585/mmwr.mm7309a2.ABSTRACTApproximately 1,000 out-of-hospital cardiac arrests (OHCAs) are assessed by emergency medical services in the United States every day, and approximately 90% of patients do not survive, leading to substantial years of potential life lost (YPLL). Chicago emergency medical services data were used to assess changes in mean age and YPLL from nontraumatic OHCA in adults in biennial cycles during 2014-2021. Among 21,070 reported nontraumatic OHCAs during 2014-2021, approximately 60% occurred among men and 57% among non-Hispanic Black or Afric...
Source: MMWR Morb Mortal Wkl... - March 7, 2024 Category: Epidemiology Authors: Shaveta Khosla Marina Del Rios Pavitra Kotini-Shah Joseph Weber Terry Vanden Hoek Illinois Heart Rescue Source Type: research

Notes from the Field: Emergency Department Visits for Unsupervised Pediatric Melatonin Ingestion - United States, 2019-2022
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):215-217. doi: 10.15585/mmwr.mm7309a5.NO ABSTRACTPMID:38451863 | DOI:10.15585/mmwr.mm7309a5 (Source: MMWR Morb Mortal Wkl...)
Source: MMWR Morb Mortal Wkl... - March 7, 2024 Category: Epidemiology Authors: Devin I Freeman Jennifer N Lind Nina J Weidle Andrew I Geller Nimalie D Stone Maribeth C Lovegrove Source Type: research

Prevalence of Self-Reported Hypertension and Antihypertensive Medication Use Among Adults - United States, 2017-2021
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):191-198. doi: 10.15585/mmwr.mm7309a1.ABSTRACTHypertension, or high blood pressure, is a major risk factor for heart disease and stroke. It increases with age and is highest among non-Hispanic Black or African American persons, men, persons aged ≥65 years, those of lower socioeconomic status, and those who live in the southern United States. Hypertension affects approximately one half of U.S. adults, and approximately one quarter of those persons have their blood pressure under control. Reducing population-level hypertension prevalence and improving control is a national priorit...
Source: MMWR Morb Mortal Wkl... - March 7, 2024 Category: Epidemiology Authors: Ahlia Sekkarie Jing Fang Donald Hayes Fleetwood Loustalot Source Type: research

Racial and Ethnic Differences in Social Determinants of Health and Health-Related Social Needs Among Adults - Behavioral Risk Factor Surveillance System, United States, 2022
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):204-208. doi: 10.15585/mmwr.mm7309a3.ABSTRACTSocial determinants of health (SDOH) are a broad array of social and contextual conditions where persons are born, live, learn, work, play, worship, and age that influence their physical and mental wellbeing and quality of life. Using 2022 Behavioral Risk Factor Surveillance System data, this study assessed measures of adverse SDOH and health-related social needs (HRSN) among U.S. adult populations. Measures included life satisfaction, social and emotional support, social isolation or loneliness, employment stability, food stability/se...
Source: MMWR Morb Mortal Wkl... - March 7, 2024 Category: Epidemiology Authors: Machell Town Paul Eke Guixiang Zhao Craig W Thomas Jason Hsia Carol Pierannunzi Karen Hacker Source Type: research

Years of Potential Life Lost and Mean Age of Adults Experiencing Nontraumatic, Out-of-Hospital Cardiac Arrests - Chicago, 2014-2021
MMWR Morb Mortal Wkly Rep. 2024 Mar 7;73(9):199-203. doi: 10.15585/mmwr.mm7309a2.ABSTRACTApproximately 1,000 out-of-hospital cardiac arrests (OHCAs) are assessed by emergency medical services in the United States every day, and approximately 90% of patients do not survive, leading to substantial years of potential life lost (YPLL). Chicago emergency medical services data were used to assess changes in mean age and YPLL from nontraumatic OHCA in adults in biennial cycles during 2014-2021. Among 21,070 reported nontraumatic OHCAs during 2014-2021, approximately 60% occurred among men and 57% among non-Hispanic Black or Afric...
Source: MMWR Morb Mortal Wkl... - March 7, 2024 Category: Epidemiology Authors: Shaveta Khosla Marina Del Rios Pavitra Kotini-Shah Joseph Weber Terry Vanden Hoek Illinois Heart Rescue Source Type: research